Showing 5931-5940 of 20432 results for "".
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://reachmd.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- Blood Eosinophils and Comorbidities in Chronic Obstructive Pulmonary Diseasehttps://reachmd.com/news/blood-eosinophils-and-comorbidities-in-chronic-obstructive-pulmonary-disease/2474823/Recent studies have established a definitive link between elevated blood eosinophil counts and both local airway inflammation and systemic inflammatory processes in patients with chronic obstructive pulmonary disease. This dual associat
- Regulatory Adjustments and COVID-19 Vaccine Distribution for High-Risk Populationshttps://reachmd.com/news/regulatory-adjustments-and-covid-19-vaccine-distribution-for-high-risk-populations/2474824/The FDA has recently delineated a shift in its COVID-19 vaccine distribution to prioritize older adults and high-risk populations. This focused approach, supported by compelling clinical and epidemiological data, is intended to decrease hospitalization
- COPD Diagnosis and Early Detection: Evaluating a New Diagnostic Frameworkhttps://reachmd.com/news/copd-diagnosis-and-early-detection-evaluating-a-new-diagnostic-framework/2474829/Traditional spirometry-based thresholds have been integral to COPD diagnosis but often overlook patients with subtle yet significant disease indicators. This new framework enriches traditional diagnostic criteria by incorporating respiratory symptoms, quality of li
- Circadian Rhythm and Fitness: Timing Activity for Healthier Aginghttps://reachmd.com/news/circadian-rhythm-and-fitness-timing-activity-for-healthier-aging/2474825/Exploring the relationship between internal circadian rhythms and physical activity uncovers promising strategies for healthier aging. Synchronizing exercise with natural energy surges not only bolsters overall fitness but also optimize
- EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Reliefhttps://reachmd.com/news/effisayil-2-spesolimab-associated-with-long-term-gpp-relief/2474835/Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. Re
- Cardiac Hypertrophy: Adaptive Mechanism and Risks of Chronic Overloadhttps://reachmd.com/news/cardiac-hypertrophy-adaptive-mechanism-and-risks-of-chronic-overload/2474814/Cardiac hypertrophy is the heart’s primary adaptation to an increased workload, marked by thickening of the ventricular wall. However, sustained overload can transform this mechanism into a pathological process characterized by ventricular dilatation a
- Gut Microbiome: SCFA Signaling and Cardiovascular Healthhttps://reachmd.com/news/gut-microbiome-scfa-signaling-and-cardiovascular-health/2474811/Groundbreaking findings have demonstrated that gut-derived SCFAs interact with receptors to offer cardiovascular protection via mechanisms like vasodilation and modulation of the renin-angiotensin system. This discovery holds critical value for bot
- Navigating Legal and Clinical Frontiers in BMP-Driven Orthopedic Surgeryhttps://reachmd.com/news/navigating-legal-and-clinical-frontiers-in-bmp-driven-orthopedic-surgery/2474802/Bone Morphogenetic Proteins (BMPs) are increasingly explored in orthopedic surgery for their potential in bone repair, although legal and regulatory changes continue to influence their application. Bone Morphogenetic Proteins (BMPs), a
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://reachmd.com/news/first-patient-dosed-with-gpx4-modulator-targeting-pathologic-senescent-cells/2475369/The first patient has been dosed with the lead drug candidate RLS-1496 in a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial, Rubedo Life Sciences, Inc., announced in a press release. The study marks the first time a glutathio